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Reply
Sir,
We would like to thank Dr Hirschberg and colleagues for
their interest in our report, which was aimed to raise aware-
ness of the rare but repeatedly described untoward effects
of deferoxamine on renal function. Moreover, we aimed to
propose a mechanism by which these untoward effects on
renal function could be mediated [2]. In the discussion we
stated that a different drug, deferasirox, has ‘been repeat-
edlyshowntocauseacuterenalfailure’quotingarecentpa-
per by Kontoghiorghes [3]. Dr Hirschberg and colleagues,
who, as members of the renal safety board for deferasirox,
had detailed knowledge of the post-marketing surveillance
data, are ‘very sceptical’ that deferasiox was responsible
for these cases of acute renal failure.
We can only refer to data available in the public do-
main. According to the FDA website, there had been
115 reports of suspected adverse drug reactions in the asso-
ciationwiththeuseofdeferasiroxfrom2November2005to
20June2006(http://www.fda.gov/cder/dsn/2007_fall/nme.
htm). Sixteen unduplicated reports described renal adverse
events. Seven patients improved after discontinuation of
deferasirox. Seven patients had ‘acute renal failure’ with
an onset between 5 and 58 days after initiation of the ther-
apy. Dr Hirschberg and colleagues state that ‘the term acute
renal failure was inappropriately used in many cases to
describe a relatively minor increase in serum creatinine
(<2×upperlimitofnormal)thatdevelopedoverthecourse
of several weeks’. Unfortunately, there had been no uni-
formly accepted definition of acute renal failure [4]. How-
ever, in a variety of settings, there is accumulating evidence
that small increments in serum creatinine are associated
with adverse outcomes [4]. Therefore, the term acute kid-
ney injury (increase of creatinine >25 µmol/l over 48 h),
which is often superimposed on pre-existing CKD, was re-
cently introduced. This definition will increase the clinical
awareness and the detection of injury to the kidney and
should, in our view, also be used in the setting of pharma-
covigilance. Aside from the FDA information, Vichinsky
et al. [5] showed in 132 adult and paediatric patients that
deferasirox administration was accompanied in a mild and
stableincrease of serumcreatinine in36.4% of thepatients.
Of the 63 patients in that study that received deferoxamine,
22.2% experienced such an increase of serum creatinine. In
contrast to deferoxamine, where the mean change in creati-
nine was 3.06 µmol/l, the mean increase in the deferasirox-
treated group was 6.3 µmol/l. Unfortunately, serum cre-
atinine only rises after a substantial loss of glomerular
filtration rate and is also influenced by many factors like
gender,weightandrace.Estimationofglomerularfiltration
rate, e.g. by measuring cystatin C, would therefore be the
preferred way to monitor renal function. Data on protein-
uria,anotherimportantmarkerofrenaldamage,aremissing
completely.
As vividly illustrated by the post-marketing information
of Novartis on deferasirox (14 May 2007), a pro-active ap-
proach to potential, even rare side effects of new drugs are
in the best interest of the public. A uniform assessment of
renal function and renal injury, e.g. by determination of
estimated GFR and proteinuria, as proposed in a science
advisory of the AHA for the assessment of patients with or
at increased risk for cardiovascular disease [1], would pro-
vide a better scientific basis for the monitoring of untoward
renal effects of new drugs.
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HDF promise for the future
Sir,
TheFebruaryissueofNephrologyDialysisTransplantation
amply reported on online haemodiafiltration (HDF) as a
possible promise for the future [1].
Please note the following erratum in Table 1 of the
Editorial Comment, concerning our study with reference
16: high-volume HDF in postdilution was compared with
C   The Author [2008].
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high-flux haemodialysis (hfHD) with regard to the removal
of beta2-microglobulin (b2M) and not with low-flux HD
(lfHD), as is reported.
Although most studies with online HDF demonstrate a
higher removal of a broad range of the molecular spec-
trum of uraemic compounds versus HD, confusion still
persists on the preferred method of HDF. With regard to
the location of inflow of the substitution fluid, most stud-
ies rely on post-, pre-, mid- or mixed dilution, but this
results in different removal rates. It is regrettable that in
several references in the Editorial Comment, even the used
HDF method was not mentioned (Table 1). Yet this is es-
sential for the knowledge of the efficiency of the treat-
ment. For instance, it is well known that with high-volume
predilution HDF, a lower clearance of small molecules
is achieved versus high-flux HD. Besides, a lower b2M
clearance is noted in high-volume predilution HDF, com-
pared with postdilution HDF with the same amount of
substitution volume (80 ml/min) [2]. In view of these re-
sults, it is not surprising that in the ongoing trials in the
NetherlandsandFrancehigh-volumeHDFinpostdilutionis
chosen.
It is also stated in the Editorial Comment that conflict-
ing results concerning phosphate clearance were reported.
When comparing phosphate removal with high-volume
(100 ml/min) HDF in postdilution, our group observed a
19% higher removal versus high-flux HD [3].
Finally—asinourdepartment,routinehigh-volumepost-
dilution HDF is performed since 1993—in dialysis patients
with more than 10 years of treatment, a lower prevalence
of carpal tunnel syndrome is reported in reference 16 of
the Editorial Comment. Concerning survival, recently our
groupreporteda26%survivalbenefit[4],comparablewith
the data of the DOPPS study and of the observational study
from Eastern Europe.
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Reply
Sir,
We thank Lornoy and De Meester for their relevant com-
ments on our recent article [1] and their correct erra-
tum concerning the applied membranes in reference 16
(Table 1).
Indeed, the location of the inflow of substitution fluid
in haemodiafiltration (HDF) is of considerable relevance
in terms of determining the efficacy of small and mid-
dle molecular weight clearance. Therefore, it is regrettable
that in many of the referenced papers in the Comment
(references 9, 32, 33, 41 and 43), the method of HDF is not
explicitly mentioned. This lack of information is particu-
larly present in the large observational studies on mortality.
So, besides the general shortcoming of observational stud-
ies, i.e. the risk of selection bias, also the different methods
ofHDFcouldhaveresultedinanevengreaterheterogeneity
in design of the studies.
Currently, more and more data on mortality rates during
HDF are being presented. Apart from De Meester et al.,
who reported a 26% survival benefit for HDF (De Meester
et al. ASN Renal Week 2007, abstract SA-PO494), a Por-
tuguese group presented their data during the 2007 ASN
meeting as well (Natario et al. ASN Renal Week 2007, ab-
stract SU-PO559). They observed in a single-center cohort
of 88 haemodialysis (HD) and HDF patients during al-
most 2 years of follow-up and after adjusting for baseline
characteristics and comorbid conditions, a 79% decrease in
mortality risk.
Recently, a 22% reduction in all-cause mortality in
patients on HDF was found in a prospective observa-
tional study performed in 757 prevalent patients in Italy
[2]. No difference in all-cause mortality was seen in pa-
tients on HDF using bags and online HDF. However,
cardiovascular mortality was lower in patients on on-
line HDF as compared to HDF using bags and to con-
ventional HD. Regrettably, again the technique of HDF
(pre- or postdilution) was not described in the method
section.
All together, these observations underscore the need
for properly designed and conducted randomized clini-
cal trials on the effect of HDF on all-cause and CV
mortality. We hope that the Dutch CONvective TRAns-
port STudy (CONTRAST), in which online postdilu-
tion HDF is applied and compared to standard HD, will
be such a study [3]. With the results of CONTRAST,
and other comparable studies [4,5], we hope that the
promising results of the large, observational studies on
HDF can be confirmed. Only then can HDF be con-
sidered no longer a ‘promise for the future’, but in-
stead an accepted treatment in terms of evidence-based
medicine.
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